Kenneth M. Rassnick
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Kenneth M. Rassnick has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
Amy Bengtson
Harrington Oncology Program, Tufts University School of Veterinary Medicine, North Grafton, MA., Tufts University School of Veterinary Medicine, North Grafton, MA
1 shared publication- Antony S. Moore
Harrington Oncology Program, Tufts University School of Veterinary Medicine, North Grafton, MA., Tufts University School of Veterinary Medicine, North Grafton, MA
1 shared publication David L. Hutto
Section of Pathology, Tufts University School of Veterinary Medicine, North Grafton, MA
1 shared publicationDavid M. Ruslander
Harrington Oncology Program, Tufts University School of Veterinary Medicine, North Grafton, MA., Tufts University School of Veterinary Medicine, North Grafton, MA
1 shared publicationHelen T. Power
Dermatology for Animals, Campbell, CA
1 shared publicationJeffrey L. Johnson
Duke Comprehensive Cancer Center, Duke University Medical Center, Durham, NC
1 shared publication
Latest Publications
- Open Access
- 1 January 2006
- Published by Wiley in Journal of Veterinary Internal Medicine
- Vol. 20 (1) , 136-143
CCNU in the Treatment of Canine Epitheliotropic Lymphoma
- 1 January 2006
- Published by Wiley in Journal of Veterinary Internal Medicine
- Vol. 20 (1) , 136-143
Open AccessCCNU in the Treatment of Canine Epitheliotropic Lymphoma
- 1 January 2001
- Published by Wiley in Journal of Veterinary Internal Medicine
- Vol. 15 (3) , 183-189
Retrospective Study of Orthovoltage Radiation Therapy for Nasal Tumors in 42 Dogs
Megavoltage radiation therapy currently is the standard of care for dogs with nasal tumors. Some studies report that surgery and adjunctive orthovoltage radiation therapy result in longer control of these tumors than does megavoltage radiation therapy alone. This study reports less effective control of nasal tumors in dogs treated with surgery and orthovoltage radiation than previously observed, supporting the superiority of megavoltage radiation therapy for these tumors. In addition, this study suggests 2 new prognostic indicators for dogs with nasal tumors and describes toxicity associated with surgery and orthovoltage therapy. Forty-two dogs with nasal tumors were treated with surgical cytoreduction and 48 Gy orthovoltage radiation therapy administered in twelve 4-Gy fractions. Median survival was 7.4 months. One- and 2-year survival rates were 37% and 17%, respectively. Dogs with facial deformity had shorter survival than those without deformity (P = .005). Dogs with resolution of clinical signs after treatment had longer survival than those with chronic nasal signs (P = .0001). Acute radiation toxicity was moderate to severe for skin and eye and negligible for oral mucosa. Toxicity healed within 1 month after radiation therapy. Late toxicity was mild, but 70% of evaluable dogs experienced persistent ocular signs. Only 39% of dogs achieved a disease-free period.
- 1 January 2001
- Published by Wiley in Journal of Veterinary Internal Medicine
- Vol. 15 (3) , 183-189
Retrospective Study of Orthovoltage Radiation Therapy for Nasal Tumors in 42 Dogs
Megavoltage radiation therapy currently is the standard of care for dogs with nasal tumors. Some studies report that surgery and adjunctive orthovoltage radiation therapy result in longer control of these tumors than does megavoltage radiation therapy alone. This study reports less effective control of nasal tumors in dogs treated with surgery and orthovoltage radiation than previously observed, supporting the superiority of megavoltage radiation therapy for these tumors. In addition, this study suggests 2 new prognostic indicators for dogs with nasal tumors and describes toxicity associated with surgery and orthovoltage therapy. Forty-two dogs with nasal tumors were treated with surgical cytoreduction and 48 Gy orthovoltage radiation therapy administered in twelve 4-Gy fractions. Median survival was 7.4 months. One- and 2-year survival rates were 37% and 17%, respectively. Dogs with facial deformity had shorter survival than those without deformity (P = .005). Dogs with resolution of clinical signs after treatment had longer survival than those with chronic nasal signs (P = .0001). Acute radiation toxicity was moderate to severe for skin and eye and negligible for oral mucosa. Toxicity healed within 1 month after radiation therapy. Late toxicity was mild, but 70% of evaluable dogs experienced persistent ocular signs. Only 39% of dogs achieved a disease-free period.